Inappropriate Adh Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Inappropriate Adh Syndrome

MalaCards integrated aliases for Inappropriate Adh Syndrome:

Name: Inappropriate Adh Syndrome ¹² ⁴⁴ ¹⁵ ⁷³

Syndrome of Inappropriate Secretion of Antidiuretic Hormone ¹² ³⁷

Syndrome of Inappropriate Antidiuretic Hormone Secretion ¹²

Syndrome of Inappropriate Vasopressin Secretion ¹²

Syndrome of Inappropriate Secretion of Adh ¹²

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Endocrine, nutritional and metabolic diseases

Disorders of other endocrine glands

Hyperfunction of pituitary gland

Syndrome of inappropriate secretion of antidiuretic hormone

External Ids:

Disease Ontology ¹² DOID:3401

ICD10 ³³ E22.2

MeSH ⁴⁴ D007177

NCIt ⁵⁰ C3988

SNOMED-CT ⁶⁸ 389983008 55004003

KEGG ³⁷ H01682

UMLS ⁷³ C0021141

Sources

Summaries for Inappropriate Adh Syndrome

MalaCards based summary : Inappropriate Adh Syndrome, also known as syndrome of inappropriate secretion of antidiuretic hormone, is related to syndrome of inappropriate antidiuretic hormone and nephrogenic syndrome of inappropriate antidiuresis, and has symptoms including polyuria An important gene associated with Inappropriate Adh Syndrome is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Neuroactive ligand-receptor interaction and Vasopressin-regulated water reabsorption. The drugs Tolvaptan and Empagliflozin have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotypes are behavior/neurological and growth/size/body region

Sources

Related Diseases for Inappropriate Adh Syndrome

Diseases related to Inappropriate Adh Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)

#	Related Disease	Score	Top Affiliating Genes
1	syndrome of inappropriate antidiuretic hormone	32.0	AQP2 AVP AVPR2 POMC
2	nephrogenic syndrome of inappropriate antidiuresis	31.8	AVP AVPR2
3	diabetes insipidus	28.3	AQP2 AVP AVPR2 POMC REN
4	bronchus cancer	10.6	AVP AVPR2
5	diabetes insipidus, nephrogenic, x-linked	10.6	AQP2 AVPR2
6	central nervous system germinoma	10.5	AVP POMC
7	seizures, sensorineural deafness, ataxia, mental retardation, and electrolyte imbalance	10.5	AQP2 AVP
8	tuberculous epididymitis	10.5	AVP POMC
9	peripheral vertigo	10.5	AQP2 AVP
10	central nervous system germ cell tumor	10.5	AVP POMC
11	secondary hypertrophic osteoarthropathy	10.5	AVP POMC
12	vestibular disease	10.5	AQP2 AVP
13	central nervous system organ benign neoplasm	10.5	AVP POMC
14	tuberculous empyema	10.5	AVPR2 POMC
15	cervix small cell carcinoma	10.5	AVP POMC
16	motion sickness	10.4	AQP1 AVP
17	chromophobe adenoma	10.4	AVP POMC
18	ectopic cushing syndrome	10.4	AVPR2 POMC
19	pancreas disease	10.3	AVP POMC
20	pituitary hormone deficiency, combined, 2	10.3	AVP POMC
21	spinal cord disease	10.3	AQP4 AVPR2
22	benign essential hypertension	10.3	AVP REN
23	idiopathic edema	10.3	AQP1 AQP2
24	pituitary gland disease	10.3	AVP POMC
25	intracranial hypertension, idiopathic	10.2	AQP1 AQP4
26	subependymoma	10.2	AQP1 AQP4
27	dysferlinopathy	10.2	AQP1 AQP4
28	acute adrenal insufficiency	10.2	POMC REN
29	acute hemorrhagic leukoencephalitis	10.2	AQP1 AQP4
30	hypoaldosteronism	10.2	POMC REN
31	adrenal cortical hypofunction	10.2	POMC REN
32	hyperaldosteronism, familial, type i	10.1	POMC REN
33	hepatorenal syndrome	10.1	AQP2 REN
34	temporal arteritis	10.1
35	small cell carcinoma	10.1
36	prostatitis	10.1
37	cerebritis	10.1
38	status asthmaticus	10.1
39	encephalitis	10.1
40	limbic encephalitis	10.1
41	familial glucocorticoid deficiency	10.1	POMC REN
42	ureteral disease	10.1	AQP2 REN
43	adrenal cortex disease	10.1	POMC REN
44	adrenal gland disease	10.1	POMC REN
45	apparent mineralocorticoid excess	10.1	POMC REN
46	neuromyelitis optica	10.1	AQP1 AQP4
47	intracranial hypertension	10.1	AQP1 AQP4
48	endocrine organ benign neoplasm	10.1	POMC REN
49	mineral metabolism disease	10.0	POMC REN
50	dracunculiasis	10.0	AVPR2 SNAI1

Graphical network of the top 20 diseases related to Inappropriate Adh Syndrome:

Sources

Symptoms & Phenotypes for Inappropriate Adh Syndrome

UMLS symptoms related to Inappropriate Adh Syndrome:

polyuria

MGI Mouse Phenotypes related to Inappropriate Adh Syndrome:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	9.95	AVP AVPR2 POMC REN AQP1 AQP2
2	growth/size/body region	MP:0005378	9.91	AQP1 AQP2 AQP4 AVPR2 POMC REN
3	hematopoietic system	MP:0005397	9.8	AQP1 AQP2 AQP4 AVPR2 POMC REN
4	homeostasis/metabolism	MP:0005376	9.8	AQP1 AQP2 AQP4 AVP AVPR2 POMC
5	mortality/aging	MP:0010768	9.76	AQP1 AQP2 AQP4 AVP AVPR2 POMC
6	nervous system	MP:0003631	9.43	SNAI1 AQP1 AQP4 AVP POMC REN
7	renal/urinary system	MP:0005367	9.17	AQP1 AQP2 AQP4 AVP AVPR2 POMC

Sources

Drugs & Therapeutics for Inappropriate Adh Syndrome

Drugs for Inappropriate Adh Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Tolvaptan

Approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

150683-30-0

216237

Synonyms:

( -)-4'-((7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl)-o-tolu-m-toluidide

150683-30-0

7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine

AC1L50C9

benzazepine derivative, 32

C116664

CHEBI:327437

CHEMBL344159

CID216237

L001628

N-[4-(7-chloro-5-hydroxy-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)-3-methylphenyl]-2-methylbenzamide

OPC 41061

OPC-41061

PDSP1_001738

PDSP2_001721

Samsca

Tolvaptan

UNII-21G72T1950

2

Empagliflozin

Approved

Phase 2, Phase 3,Phase 3

864070-44-0

3

Natriuretic Agents

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

4

Hormones

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

5

Vasopressins

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

6

Arginine Vasopressin

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

7

Satavaptan

Phase 3,Phase 2

185913-78-4

7029

8

Coagulants

Phase 3,Phase 2,Phase 1

9

Hemostatics

Phase 3,Phase 2,Phase 1

10

Deamino Arginine Vasopressin

Phase 2, Phase 3

11

Hormone Antagonists

Phase 3,Phase 2,Phase 1

12

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3,Phase 2,Phase 1

13

Vasoconstrictor Agents

Phase 3,Phase 2,Phase 1

14

Hypoglycemic Agents

Phase 2, Phase 3,Phase 3

15

Pharmaceutical Solutions

Phase 2, Phase 3

16

arginine

Nutraceutical

Phase 3,Phase 2,Phase 1

17

Probenecid

Approved, Investigational

Phase 1, Phase 2

57-66-9

4911

Synonyms:

4-((dipropylamino)Sulfonyl)benzoate

4-((dipropylamino)Sulfonyl)benzoic acid

4-((Dipropylamino)sulfonyl)benzoic acid

4-((dipropylamino)Sulphonyl)benzoate

4-((dipropylamino)Sulphonyl)benzoic acid

4-(Di-n-propylsulfamoyl)benzoesaeure

4-(Di-N-propylsulfamoyl)benzoesaeure

4-(Di-N-propylsulphamoyl)benzoesaeure

4-(Dipropylsulfamoyl)benzoic acid

4-(N,N-Dipropylsulfamoyl)benzoesaeure

4-(N,N-Dipropylsulphamoyl)benzoesaeure

4-[(dipropylamino)sulfonyl]benzoic acid

57-66-9

AB00052080

AC1L1J86

AC1Q2XQM

AC1Q2XQN

AC-2023

AI3-50078

AKOS000165123

Apurina

Bencid

Benecid

Benemid

Benemid (TN)

Benemide

Benuryl

BIDD:GT0626

BIDD:PXR0092

Biokanol brand OF probenecid

Biokanol Brand of Probenecid

BPBio1_000643

BRD-K95237249-001-05-9

BRN 2815775

BSPBio_000583

BSPBio_002227

C07372

C13H19NO4S

CAS-57-66-9

CCRIS 3643

CHEBI:177474

CHEMBL897

CID4911

Colbenemid

Col-BENEMID

ColBenemid (co mponent of)

ColBenemid (component of)

Col-Probenecid

CPD000058280

D00475

D011339

DB01032

DivK1c_000056

EINECS 200-344-3

HMS1569N05

HMS1920J22

HMS2092C03

HMS500C18

HSDB 3387

I01-1905

ICN brand OF probenecid

ICN Brand of Probenecid

IDI1_000056

IDIS brand OF probenecid

IDIS Brand of Probenecid

KBio1_000056

KBio2_001314

KBio2_003882

KBio2_006450

KBio3_001727

KBioGR_000971

KBioSS_001314

LS-33

Major brand OF probenecid

Major Brand of Probenecid

Martec brand OF probenecid

Martec Brand of Probenecid

Merck brand OF probenecid

Merck Brand of Probenecid

MLS000028496

MLS001076472

MolPort-000-145-935

NCGC00016251-01

NCGC00016251-02

NCGC00023829-03

NCGC00023829-04

NCGC00023829-05

NCGC00023829-06

NCI-C56097

NINDS_000056

NSC 18786

NSC18786

Ophthalmic brand OF probenecid

Ophthalmic Brand of Probenecid

Oprea1_416955

P-(Dipropylsulfamoyl)benzoate

p-(Dipropylsulfamoyl)benzoic acid

P-(Dipropylsulfamoyl)benzoic acid

p-(Dipropylsulfamyl)benzoic acid

P-(Dipropylsulphamoyl)benzoate

P-(Dipropylsulphamoyl)benzoic acid

p-[Dipropylsulfamoyl]benzoic acid

P8761_SIGMA

Panuric

Parabenem

Parmed brand OF probenecid

Parmed Brand of Probenecid

Polycillin-BRB

Polycillin-PRB

Polycillin-PRB (component of)

Prestwick_809

Prestwick0_000542

Prestwick1_000542

Prestwick2_000542

Prestwick3_000542

Probalan

Probampacin

Probecid

Proben

Proben-C

probenecid

Probenecid (JP15/USP/INN)

Probenecid [INN:BAN:JAN]

Probenecid acid

Probenecid Acid

Probenecid major brand

Probenecid Major Brand

Probenecid martec brand

Probenecid Martec Brand

Probenecid parmed brand

Probenecid Parmed Brand

Probenecid weimer

Probenecid Weimer

Probenecid zenith brand

Probenecid Zenith Brand

Probenecida

Probenecida [INN-Spanish]

Probenecide

Probenecide [INN-French]

Probenecidum

Probenecidum [INN-Latin]

Probenemid

probenicid

Probenicid

Probenid

Probexin

pro-Cid

Pro-Cid

Prolongine

Robenecid

SAM002554923

SBB028597

SMR000058280

SPBio_001327

SPBio_002504

Spectrum_000834

SPECTRUM1500502

Spectrum2_001294

Spectrum3_000554

Spectrum4_000486

Spectrum5_001419

Sulprin

Synergid R

Tubophan

UNII-PO572Z7917

Uricosid

Urocid

Valdecasas brand OF probenecid

Valdecasas Brand of Probenecid

WLN: QVR DSWN3&3

Zenith brand OF probenecid

Zenith Brand of Probenecid

18

Acetylcysteine

Approved, Investigational

Phase 1, Phase 2

616-91-1

12035

Synonyms:

(2R)-2-acetylamino-3-Sulfanylpropanoate

(2R)-2-acetylamino-3-sulfanylpropanoic acid

(2R)-2-acetylamino-3-Sulfanylpropanoic acid

(2R)-2-acetylamino-3-Sulphanylpropanoate

(2R)-2-acetylamino-3-Sulphanylpropanoic acid

(R)-2-acetylamino-3-Mercaptopropanoate

(R)-2-acetylamino-3-mercaptopropanoic acid

(R)-2-acetylamino-3-Mercaptopropanoic acid

(R)-Mercaptate

(R)-Mercaptic acid

(R)-mercapturic acid

(R)-Mercapturic acid

2-acetylamino-3-mercapto-Propionate

2-acetylamino-3-mercapto-Propionic acid

Ac pharma brand OF acetylcysteine

ACC

Acebraus

Acemuc

Acetabs

Acetadote

Acetilcisteina

Acetylcystein al

Acetylcystein atid

Acetylcystein heumann

Acetylcystein trom

Acetylcystein, mentopin

Acetylcysteine ac-pharma brand

Acetylcysteine alcon brand

Acetylcysteine aluid brand

Acetylcysteine atid brand

Acetylcysteine azupharma brand

Acetylcysteine betapharm brand

Acetylcysteine bioiberica brand

Acetylcysteine bouchara brand

Acetylcysteine centrafarm brand

Acetylcysteine disphar brand

Acetylcysteine farmasan brand

Acetylcysteine fresenius brand

Acetylcysteine génévrier brand

Acétylcystéine GNR

Acetylcysteine GNR-pharma brand

Acetylcysteine guerbet brand

Acetylcysteine hermes brand

Acetylcysteine heumann brand

Acetylcysteine hydrochloride

Acetylcysteine inpharzam brand

Acetylcysteine intra brand

Acetylcysteine klinge brand

Acetylcysteine krewel brand

Acetylcysteine lichtenstein brand

Acetylcysteine lindopharm brand

Acetylcysteine merck brand

Acetylcysteine oberlin brand

Acetylcysteine pfleger brand

Acetylcysteine pharbita brand

Acetylcysteine roberts brand

Acetylcysteine sodium

Acetylcysteine temmler brand

Acetylcysteine teva brand

Acetylcysteine thiemann brand

Acetylcysteine trommsdorff brand

Acetylcysteine upsa brand

Acetylcysteine whitehall brand

Acetylcysteine zambon brand

Acetylcysteine zinc

Acetylcysteine zyma brand

Acetylcysteine, (D)-isomer

Acetylcysteine, (DL)-isomer

Acetylcysteine, monoammonium salt

Acetylcysteine, monosodium salt

Acetylcysteinum

Acetylin

Acetyst

Acid, mercapturic

Ac-pharma brand OF acetylcysteine

Airbron

Alcon brand OF acetylcysteine

Allen and hanburys brand OF acetylcysteine

Aluid brand OF acetylcysteine

Alveolex

Atid brand OF acetylcysteine

Azubronchin

Azupharma brand OF acetylcysteine

Betapharm brand OF acetylcysteine

Bioiberica brand OF acetylcysteine

Bisolvon nac

Boehringer ingelheim brand OF acetylcysteine

Bouchara brand OF acetylcysteine

Bristol myers squibb brand OF acetylcysteine

Bristol myers squibb brand OF acetylcysteine sodium salt

Bristol-myers squibb brand OF acetylcysteine

Bristol-myers squibb brand OF acetylcysteine sodium salt

Bromuc

broncho Fips

broncho-Fips

BronchoFips

Broncholysin

Broncoclar

Centrafarm brand OF acetylcysteine

Codotussyl

Cystamucil

dampo Mucopect

Dey brand OF acetylcysteine sodium salt

Disphar brand OF acetylcysteine

Durabronchal

Eurespiran

Exomuc

Fabrol

Farmasan brand OF acetylcysteine

Fluimicil infantil

Fluimucetin

Fluimucil

Flumucetin

Fluprowit

Frekatuss

Fresenius brand OF acetylcysteine

Genac

Génévrier brand OF acetylcysteine

GNR Pharma brand OF acetylcysteine

GNR-Pharma brand OF acetylcysteine

Guerbet brand OF acetylcysteine

Hermes brand OF acetylcysteine

Heumann brand OF acetylcysteine

Hoestil

Hustengetränk, optipect

Hydrochloride, acetylcysteine

Ilube

Inpharzam brand OF acetylcysteine

Intra brand OF acetylcysteine

Jenacystein

Jenapharm

Klinge brand OF acetylcysteine

Krewel brand OF acetylcysteine

L-a-acetamido-b-Mercaptopropionate

L-a-acetamido-b-Mercaptopropionic acid

L-acetylcysteine

L-Acetylcysteine

L-alpha-acetamido-beta-Mercaptopropionate

L-alpha-acetamido-beta-Mercaptopropionic acid

Lantamed

Larylin nac

Lichtenstein brand OF acetylcysteine

Lindocetyl

Lindopharm brand OF acetylcysteine

Lysox

L-α-acetamido-β-mercaptopropionate

L-α-acetamido-β-mercaptopropionic acid

m Pectil

Mentopin acetylcystein

Mercaptate

Mercaptic acid

Mercapturic acid

Merck brand OF acetylcysteine

Monoammonium salt acetylcysteine

Monosodium salt acetylcysteine

m-Pectil

MPectil

Muciteran

muco Sanigen

Mucolysin

Mucomyst

Mucopect, dampo

Mucosil

Mucosol

Mucosolvin

N Acetyl L cysteine

N Acetylcysteine

NAC

NAC al

NAC zambon

NAC, bisolvon

N-Acetyl-3-mercaptoalanine

N-acetylcysteine

N-Acetylcysteine

N-Acety-L-cysteine

N-acetyl-L-(+)-cysteine

N-Acetyl-L-(+)-cysteine

N-acetyl-L-cysteine

Oberlin brand OF acetylcysteine

Optipect hustengetränk

Parvolex

Pfleger brand OF acetylcysteine

Pharbita brand OF acetylcysteine

Produpharm lappe brand OF acetylcysteine

Roberts brand OF acetylcysteine

Roche nicholas brand OF acetylcysteine

Sanigen, muco

Siccoral

Siran

Sodium 2-acetamido-3-mercaptopropionate

Sodium, acetylcysteine

Solmucol

Temmler brand OF acetylcysteine

Teva brand OF acetylcysteine

Thiemann brand OF acetylcysteine

Trommsdorff brand OF acetylcysteine

UPSA brand OF acetylcysteine

Whitehall brand OF acetylcysteine

Zambon brand OF acetylcysteine

Zambon, nac

Zinc, acetylcysteine

Zyma brand OF acetylcysteine

19

Renal Agents

Phase 1, Phase 2

20

Respiratory System Agents

Phase 1, Phase 2

21

N-monoacetylcystine

Phase 1, Phase 2

22

Expectorants

Phase 1, Phase 2

23

Antidotes

Phase 1, Phase 2

24

Anti-Infective Agents

Phase 1, Phase 2

25

Antioxidants

Phase 1, Phase 2

26

Protective Agents

Phase 1, Phase 2

27

Antirheumatic Agents

Phase 1, Phase 2

28

Antiviral Agents

Phase 1, Phase 2

29

cysteine

Nutraceutical

Phase 1, Phase 2

Interventional clinical trials:

(show all 22)

#	Name	Status	NCT ID	Phase	Drugs
1	Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine	Withdrawn	NCT00298753	Phase 4
2	Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia	Unknown status	NCT01507727	Phase 2, Phase 3	Tolvaptan;Placebo
3	Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion	Completed	NCT00264914	Phase 3	SR121463B
4	Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion	Completed	NCT00264927	Phase 3	SR121463B
5	Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study	Completed	NCT02729766	Phase 2, Phase 3	Empagliflozin 25mg Tbl;Placebo P-Tablet
6	"SALT-2 Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia	Completed	NCT00201994	Phase 3	Tolvaptan
7	“SALT Trial” Study of Ascending Levels of Tolvaptan in Hyponatremia	Completed	NCT00072683	Phase 3	tolvaptan
8	A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH	Recruiting	NCT03048747	Phase 3	Tolvaptan Oral Tablet
9	Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study	Recruiting	NCT03202667	Phase 2, Phase 3	Empagliflozin 25mg;Placebo
10	Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study	Enrolling by invitation	NCT02874807	Phase 2, Phase 3	Empagliflozin
11	A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia	Terminated	NCT00728091	Phase 3	Satavaptan;placebo
12	Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia	Terminated	NCT01227512	Phase 3	tolvaptan
13	Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion	Completed	NCT00032734	Phase 2	satavaptan (SR121463B)
14	A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)	Completed	NCT02009878	Phase 1, Phase 2	tolvaptan
15	Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury	Completed	NCT01322009	Phase 1, Phase 2	Probenecid and N-acetyl cysteine;Placebo
16	Subclassification of the Syndrome of Inappropriate ADH Secretion	Completed	NCT01341665
17	An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH	Completed	NCT02545101
18	An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain	Completed	NCT02548845
19	An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy	Completed	NCT02573077
20	Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia	Completed	NCT01240668
21	Evaluation of Plasma Volume Using Ultrasound in Disorders of Fluid With Sodium	Active, not recruiting	NCT01547650
22	Fractional Urate Excretion in Nonedematous Hyponatremia	Withdrawn	NCT01425125	Not Applicable	Tolvaptan in euvolemic hyponatremia

Search NIH Clinical Center for Inappropriate Adh Syndrome

Cochrane evidence based reviews: inappropriate adh syndrome

Sources

Genetic Tests for Inappropriate Adh Syndrome

Sources

Anatomical Context for Inappropriate Adh Syndrome

MalaCards organs/tissues related to Inappropriate Adh Syndrome:

⁴¹

Brain

Sources

Publications for Inappropriate Adh Syndrome

Articles related to Inappropriate Adh Syndrome:

#	Title	Authors	Year
1	Case of inappropriate ADH syndrome: hyponatremia due to polyethylene glycol bowel preparation. ( 25232272 )	Ko S.H....Oh H.J.	2014
2	Hyponatraemia and the inappropriate ADH syndrome in pneumonia. ( 1283678 )	Dhawan A....Singhi S.	1992
3	How to recognize and treat the inappropriate ADH syndrome. ( 1214567 )	Noel G.L.	1975
4	Urinary antidiuretic hormone in polyuric disorders and in inappropriate ADH syndrome. ( 4343077 )	Miller M....Moses A.M.	1972
5	Correction of an inappropriate ADH syndrome by tumor resection. ( 5636059 )	Tisher C.C.	1968
6	Antidiuretic principle in malignant tumor extracts from patients with inappropriate ADH syndrome. ( 5688815 )	Vorherr H....Kleeman C.R.	1968

Sources

Genes for Inappropriate Adh Syndrome

Genes related to Inappropriate Adh Syndrome (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	AVP	Arginine Vasopressin	Protein Coding	19.6	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
2	AVPR2	Arginine Vasopressin Receptor 2	Protein Coding	17.16	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
3	AQP2	Aquaporin 2	Protein Coding	17.16	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	POMC	Proopiomelanocortin	Protein Coding	15.78	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	AQP4	Aquaporin 4	Protein Coding	15.34	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	REN	Renin	Protein Coding	14.97	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
7	SNAI1	Snail Family Transcriptional Repressor 1	Protein Coding	14.76	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
8	AQP1	Aquaporin 1 (Colton Blood Group)	Protein Coding	14.54	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Inappropriate Adh Syndrome

Sources

Expression for Inappropriate Adh Syndrome

Search GEO for disease gene expression data for Inappropriate Adh Syndrome.

Sources

Pathways for Inappropriate Adh Syndrome

Pathways related to Inappropriate Adh Syndrome according to KEGG:

³⁷

#	Name	Kegg Source Accession
1	Neuroactive ligand-receptor interaction	hsa04080
2	Vasopressin-regulated water reabsorption	hsa04962

Pathways related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds ⁶⁶ Show member pathways Bicarbonate transporters ⁶⁶ Cation-coupled Chloride cotransporters ⁶⁶ Class II GLUTs ⁶⁶ Facilitative Na+-independent glucose transporters ⁶⁶ Inositol transporters ⁶⁶ Multifunctional anion exchangers ⁶⁶ Na+/Cl- dependent neurotransmitter transporters ⁶⁶ Na+-dependent glucose transporters ⁶⁶ Organic anion transport ⁶⁶ Organic anion transporters ⁶⁶ Organic cation transport ⁶⁶ Organic cation/anion/zwitterion transport ⁶⁶ Proton/oligopeptide cotransporters ⁶⁶ Proton-coupled monocarboxylate transport ⁶⁶ Rhesus glycoproteins mediate ammonium transport. ⁶⁶ SLC-mediated transmembrane transport ⁶⁶ Sodium/Calcium exchangers ⁶⁶ Sodium/Proton exchangers ⁶⁶ Sodium-coupled phosphate cotransporters ⁶⁶ Sodium-coupled sulphate, di- and tri-carboxylate transporters ⁶⁶ Transmembrane transport of small molecules ⁶⁶ Transport of inorganic cations/anions and amino acids/oligopeptides ⁶⁶ Type II Na+/Pi cotransporters ⁶⁶	12.78	AQP1 AQP2 AQP4 AVP AVPR2
2	Aquaporin-mediated transport ⁶⁶ Show member pathways Cytoskeleton remodeling Role of PKA in cytoskeleton reorganisation ²² Glucagon signaling in metabolic regulation ⁶⁶ Glucagon-like Peptide-1 (GLP1) regulates insulin secretion ⁶⁶ Passive transport by Aquaporins ⁶⁶ Transport of glycerol from adipocytes to the liver by Aquaporins ⁶⁶ Vasopressin regulates renal water homeostasis via Aquaporins ⁶⁶	11.77	AQP1 AQP2 AQP4 AVP AVPR2
3	G alpha (s) signalling events ⁶⁶	11.5	AVP AVPR2 POMC
4	Bile secretion ³⁷	11.22	AQP1 AQP4
5	Renin secretion ³⁷	11.13	AQP1 REN
6	Vasopressin-regulated water reabsorption ³⁷	10.57	AQP2 AQP4 AVP AVPR2

Sources

GO Terms for Inappropriate Adh Syndrome

Cellular components related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	clathrin-coated vesicle membrane	GO:0030665	8.96	AVP AVPR2
2	basolateral plasma membrane	GO:0016323	8.8	AQP1 AQP2 AQP4

Biological processes related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	ion transmembrane transport	GO:0034220	9.67	AQP1 AQP2 AQP4
2	negative regulation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0043154	9.54	AQP1 AVP
3	regulation of blood pressure	GO:0008217	9.52	POMC REN
4	generation of precursor metabolites and energy	GO:0006091	9.51	AVP POMC
5	excretion	GO:0007588	9.48	AQP2 AVPR2
6	positive regulation of vasoconstriction	GO:0045907	9.46	AVP AVPR2
7	cellular response to copper ion	GO:0071280	9.43	AQP1 AQP2
8	glycerol transport	GO:0015793	9.4	AQP1 AQP2
9	positive regulation of systemic arterial blood pressure	GO:0003084	9.37	AVP AVPR2
10	multicellular organismal water homeostasis	GO:0050891	9.33	AQP1 AQP4 AVP
11	cellular response to mercury ion	GO:0071288	9.32	AQP1 AQP2
12	renal water transport	GO:0003097	9.26	AQP1 AQP2
13	water transport	GO:0006833	9.26	AQP1 AQP2 AQP4 AVP
14	renal water homeostasis	GO:0003091	9.02	AQP1 AQP2 AQP4 AVP AVPR2

Molecular functions related to Inappropriate Adh Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	channel activity	GO:0015267	9.33	AQP1 AQP2 AQP4
2	neuropeptide hormone activity	GO:0005184	9.32	AVP POMC
3	glycerol transmembrane transporter activity	GO:0015168	9.26	AQP1 AQP2
4	water channel activity	GO:0015250	9.13	AQP1 AQP2 AQP4
5	water transmembrane transporter activity	GO:0005372	8.8	AQP1 AQP2 AQP4

Sources

Sources for Inappropriate Adh Syndrome

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia